Retatrutide is a novel therapeutic/treatment/medicine agent under investigation for the management/treatment/control of type 2 diabetes. It belongs to a class of drugs known as GLP-1 receptor agonists/glucagon-like peptide-1 receptor agonists/glucose-dependent insulinotropic polypeptide agonists, which work by stimulating/activating/enhancing the r

Showing promise in the arena of excess body fat therapy, retatrutide presents a distinct approach. Beyond many current medications, retatrutide works as a dual agonist, at once targeting both glucagon-like peptide-1 (GLP-1) and glucose-sensitive insulinotropic substance (GIP) binding sites. The simultaneous stimulation encourages various helpful ef